ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed Net Margin for 4 consecutive years, with 363.14% as the latest value for Q4 2025.
- Quarterly Net Margin rose 30305.0% to 363.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 42.7% through Dec 2025, down 4465.0% year-over-year, with the annual reading at 203.25% for FY2025, 20294.0% down from the prior year.
- Net Margin hit 363.14% in Q4 2025 for ARS Pharmaceuticals, up from 163.66% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 363.14% in Q4 2025 to a low of 206030.0% in Q2 2023.
- Historically, Net Margin has averaged 25847.52% across 4 years, with a median of 1061.19% in 2024.
- Biggest five-year swings in Net Margin: tumbled -20466276bps in 2023 and later surged 20296200bps in 2024.
- Year by year, Net Margin stood at 3507.94% in 2022, then plummeted by -5773bps to 206030.0% in 2023, then surged by 100bps to 60.08% in 2024, then soared by 504bps to 363.14% in 2025.
- Business Quant data shows Net Margin for SPRY at 363.14% in Q4 2025, 163.66% in Q3 2025, and 302.95% in Q2 2025.